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ÖZET
Cisplatin  (CDDP),  siklofosfamit  (CY),  metotreksat  (MTX)  and  vinblastin  (VINB)  tümör 
tipine bağlı olarak, farklı kombinasyonlar içinde kullanılan kemoterapötik ajanlardır. CDDP, 
uterus kanserinde; CY, meme ve akciğer kanserlerinde; MTX , sindirim sistemi kanserinde; 
VINB ise böbrek kanserlerinde kullanılan kemoterapotik kokteyllerin bileşenleridir.
Butirilkolinesteaz (BChE; E.C. 3.1.1.8) farklı organizmaların birçok dokusu ve vücut sıvında 
bulunan  bir  detoksifikasyon  enzimidir.  Bu  çalışmamızda,  dört  anti-tumoral  ilacın  kanser 
tedavisinde kullanılan dozlarında, sıçan ince barsağından saflaştırdığımız BChE’nin çözünür 
formuyla moleküler seviyedeki etkileşimlerini araştırdık. 
Çalışılan dört ilacın enzim üzerinde zamanla oluşturduğu inhibisyonun, sıfırıncı dakikada 
oluşan hızlı bir inhibisyon olup, 60 dak. boyunca değişmeden korunduğu tespit edildi. Bu 
sonuçlar, ilaçların BChE’nin tersinir inhibitörleri olduğunu gösterir.
İlaçların artan derişimlerine karşılık BChE aktivitesinin giderek azaldığı bulundu. Her ilacın 
1mM’lık derişimlerinin enzim üzerindeki inhibisyon yüzdeleri kıyaslandığında, MTX’in % 
15, VINB’nin % 25, CY’nin % 60 ve CDDP’nin % 75 oranında BChE aktivitesini azalttığı 
tespit edildi. Kanser terapisinde hastalara MTX ve VINB, 1-25 nM derişimde verildiğinden, 
bu aralıkta BChE üzerinde inhibitör etkilerinin görülmeyeceği söylenebilir. Diğer yandan,   
CY ve CDDP 100-200 µM derişimlerde kullanılmaktadır ve bu aralıkta BChE aktivitesini 
yaklaşık % 30 azaltırlar. Bu yüzden bu iki ilacın in vivo olarak BChE aktivitesini azaltması 
beklenebilir.
Çalışılan  ilaçlar  içinde,  cisplatin  diğerlerine  göre  en  etkin  inhibitör  olarak  tespit  edildiği 
için inhibisyon kinetiği de çalışıldı ve CDDP’nin enzimin saf kompetitif inhibitörü olduğu 
saptandı. Ki değeri 0.080 ± 0.013 mM olarak hesaplandı.
Anahtar  Kelimeler: Butirilkolinesteraz,  cisplatin,  siklofosfamit,  metotreksat, 
vinblastin, inhibisyon kinetiği, sıçan incebarsağı
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ABSTRACT
Cysplatin (CDDP), cyclophosphamide (CY), methotrexate (MTX) and vinblastine (VINB) 
are chemotherapeutic agents used respectively in uterus, breast and lung, digestive tract and 
kidney cancer treatment, in different combinations with other chemotherapeutic agents. 
Butyrylcholinesterase (BChE) is a major detoxification enzyme found in many tissues and 
body  fluids  of  different  organisms.  Here,  we  investigated  the  effects  of  these  drugs  on 
soluble BChE purified from rat small intestine, at the concentration in ranges used in cancer 
therapy. 
The time-dependent inhibitions of BChE by the drugs studied were found to be rapid. The
initial inhibition percentage for each drug at zero time was stable for 60 minutes displaying 
that these drugs might be the reversible inhibitors of BChE.   
BChE activity was decreased by increasing the drug concentrations. Comparison of inhibitory
effects of the corresponding drugs, at 1 mM concentration, revealed the inhibition percentages 
of 15%, 25%, 60% and 75% for MTX, VINB, CY and CDDP, respectively. MTX and VINB, 
at the concentrations used in therapy, 1-25 nM, will have no inhibitory effect on BChE. CY 
and CDDP are used at therapeutic concentrations of 100-200 �M at which BChE was inhib-
ited approximately by 30% thus these drugs may inhibit BChE in vivo.
Among studied drugs, cysplatin was found to be the most effective inhibitor within its chemo-
therapeutic range. Hence, inhibition kinetics of CDDP was studied in detail. CDDP was found 
as a pure competitive inhibitor of BChE with a Ki value calculated as 0.080 ± 0.013 mM.
Key  Words: Butyrylcholinesterase,  cysplatin,  cyclophosphamide,  methotrexate, 
vinblastine,  inhibition kinetics, rat intestine287 Turk J Biochem, 2004; 29(4); 286-289. Yıldız et al.
INTRODUCTION
Butyrylcholinesterase (BChE; acylcholine acylhydrola-
se, E.C. 3.1.1.8) is found in many tissues and body fluids 
of the vertebrates (1-3). Although its native substrate(s)
and its biological significance are still unknown, it has 
been shown that BChE is involved in the extra-hepatic 
hydrolytic transformation of a number of ester-contain-
ing  drugs  and  xenobiotics.  As  a  detoxifying  enzyme, 
BChE  bioscavenges  succinyldicholine  (muscle  relax-
ant) (4), organophosphate and carbamate esters (pesti-
cides, insecticides and drugs for treatment of glaucoma, 
Alzheimer  Disease  etc.)(5),  cocaine  (6),  aspirin  (7), 
amitriptyline (antidepressant)(8), benactyzine and dro-
fenine  (anticonvulsants)(9)  etc.,  however  it  converts 
some prodrugs to their active forms such as bambuterol 
(antiasthmatic) (10), heroin (11), irinotecan (anticancer 
prodrug) (12) etc.
Cancer patients are treated with many drugs and pro-
drugs that are metabolized or eliminated by esterases 
in the extra-hepatic tissues and body fluids. Cysplatin 
(CDDP) which is used for treatment of uterus cancer, 
cyclophosphamide (CY) which is used for breast and 
lung  cancer,  methotrexate  (MTX)  which  is  used  for 
digestive tract cancer and vinblastine (VINB) which is 
used for kidney cancer are chemotherapeutic agents that 
are used in different combinations depending on the type 
of tumor. Puche, E. and Perea, M. (13) declared that 
BChE activity was clearly decreased within 24 hrs after 
the first session of chemotherapy.
In  this  study,  we  investigated  the  mechanism  of  the 
interaction of these four anticancer drugs on BChE puri-
fied from rat small intestine within their chemotherapeu-
tic concentration ranges used in anticancer therapy.
MATERIALS AND METHODS
Materials
3-(N-Morpholino)  propanesulfonic  acid  (MOPS),  5-
5’-dithiobis  (2-nitrobenzoic  acid)(DTNB),  procaina-
mide  hydrochloride,  Sepharose  4B,  N-N’  methylen 
bis-acrylamide, Trizma base, ethopropazine were pur-
chased from Sigma (USA). S-n-butyrylthiocholine ioide 
(BTCh),  acrylamide,  bovine  serum  albumin  (BSA), 
Coommassie  Brilliant  Blue  R-250  were  from  BDH 
(UK). Coommassie Brilliant Blue G-250 was purchased 
from Serva (Germany). All other chemicals used were of 
the best analytical grade.
Purification of BChE from rat small intestine 
In this study, small intestines were obtained from female 
Wistar rats killed for students’ laboratory coursework at 
Hacettepe  University  Medical  School.  Soluble  BChE 
isoform was purified about 260 fold from rat intestine 
with a procedure previously reported including Sephadex 
G-25 chromatography and procainamide-Sepharose 4B 
affinity chromatography (14).
Enzyme Assay
BChE  activity  was  measured  on  Shimadzu  UV-1601 
spectrophotometer by the method of Ellman G.L. et.al 
(15) by using butyrylthiocholine (BTCh) as substrate. 
Initial  velocities  were  measured  at  37°C,  in  one  mL
assay mixture, composed of 100 mM MOPS buffer, pH 
7.4,  0.25  mM  DTNB,  182.5  ng  purified  enzyme  and 
various concentrations of BTCh; from 0.25 to 4.0 mM. 
CDDP, CY, MTX dissolved in 100 mM MOPS buffer, 
pH 7.4 and VINB dissolved in 100 mM MOPS buffer, 
pH 7.4 containing 10 % dimethyl sulfoxide were used 
in kinetic studies. In the measurements, the spontane-
ous hydrolysis of BTCh and the effects of CDDP, CY, 
MTX, VINB and dimethyl sulfoxide on substrate have 
been eliminated using different blank tubes containing 
the necessary combinations of compounds. One unit of 
BChE is defined as the amount of enzyme which cata-
lyzes the formation of 1µmole product per min under the 
conditions mentioned above.
Protein determination 
Protein  contents  in  the  chromatography  steps  during 
purification procedure were followed by measuring the 
absorbance at 280 nm. In the pooled samples at each 
purification  step,  protein  concentrations  were  deter-
mined  by  the  micro  method  of  Bradford,  M.M.  (16) 
using BSA as standard.
Analysis of the kinetic data
The kinetic data were analyzed and the kinetic constants 
were calculated by means of the non-linear curve fitting 
module of Systat (version 9.0) statistical software.
RESULTS AND DISCUSSION
Butyrylcholinesterase is one of the major detoxification 
enzymes that hydrolyze the natural and the synthetic car-
boxylic or phosphoric acid ester-bond containing com-
pounds (1). The enzyme plays an important role in the 
bioscavenging of some drugs such as succinyldicholine, 
organophosphate and carbamate esters, cocaine, aspirin, 
amitriptyline, benactyzine and drofenine; or activating 
of some drugs such as bambuterol heroin, irinotecan (4-
12). Puche, E. and Perea, M. (13) reported that plasma 
BChE activity decreased within 24 hrs in the patients 
diagnosed as having initial stage primary carcinoma of 
breast, digestive tract, lung, uterus or kidney, after the 
first treatment with chemotherapy cocktails. This effect 
was also independent of sex, age, location of the tumor 
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we wonder what the effects of individual drug of chemo-
therapy cocktails on BChE at molecular level are. In this 
study, we used BChE purified from rat small intestine 
and we chose the four chemotherapeutic agents used for 
different tumor types: Cysplatin (CDDP) which is used 
for treatment of uterus cancer, cyclophosphamide (CY) 
which is used for breast and lung cancer, methotrexate 
(MTX) which is used for digestive tract cancer and vin-
blastine (VINB) which is used for kidney cancer.
Time-Dependent  Effects  of  Cancer  Drugs  on  Rat 
Intestinal BChE
To investigate the effect of 25 µM CDDP or CY and 
50 µM VINB or MTX, they are preincubated with the 
enzyme  at  370C  and  at  indicated  times  shown  in  the 
Figure 1, aliquots were transferred to assay mixture con-
taining 4 mM BTCh as substrate.
As seen in the Fig.1, the time-dependent inhibitions of 
the enzyme by cancer drugs were rapid and, the initial 
inhibition percentage obtained for each drug at zero time 
did not change for 60 minutes. These results showed that 
cancer drugs might be reversible inhibitors of BChE.
The  Concentration  Dependent  Effects  of  Cancer 
Drugs on BChE activity 
The increasing concentrations of these drugs decreased 
the  rat  intestinal  BChE  activity.  When  the  inhibitory 
effects of 1 mM of these drugs were compared, inhibi-
tory percentages were found to be 15%, 25%, 60% and 
75% for MTX, VINB, CY and CDDP, respectively (Fig. 
2). 
In cancer therapy, MTX and VINB are generally used 
at 1-25 nM concentrations. In vitro, at these drug con-
centrations, no inhibitory effect on BChE activity will 
be expected. However, when CY and CDDP were used 
at  therapeutic  concentrations  (100-200  µM),  approxi-
mately  20-30%  inhibition  in  the  BChE  activity  was 
observed (Fig.2).
Kinetic  Behavior  of  Rat  Intestinal  BChE  with 
CDDP
Among the studied drugs, cysplatin was seen as a more 
effective inhibitor than cyclophosphamide, methotrexate 
and vinblastine for rat intestinal BChE within its chemo-
therapeutic concentration ranges (Fig.2). Therefore, inhi-
bition kinetics of CDDP on the enzyme was studied.
In the Lineweaver- Burk plot, the control and inhibitory 
lines intersected in 1/Vm value (Fig. 3). Application of 
the data to the non-linear regression module of Systat 
(version  9.0)  software  fitted  the  kinetic  modeling  to 
pure competitive inhibition. The kinetic parameters, Ks 
and Vm of rat intestinal BChE were found to be 0.700 
± 0.123 mM and 0.035 ± 0.002 µmole/min/mg protein, 
respectively. Ki was calculated as 0.080 ± 0.013 mM
(17).
The soluble isoform of rat intestinal BChE has tetramer-
ic globular structure similar to that of serum BChE (14). 
Each monomer of the enzyme molecule contains a 20Å 
deep and narrow active site cavity lined with approxi-
mately 55 residues (18). It is known that two regions 
of this cavity involve Zn2+-binding site. One of these 
regions is near by peripheral anionic site (PAS), which 
is found at the rim of active site cavity and responsible of 
first binding of a positively-charged substrate. The other 
is localized close to the esteratic site of active center, 
which  is  located  at  the  bottom  of  cavity.  Ni2+,  Co2+
and Mn2+ are competitive for the zinc binding site (19). 
Similarly, as a competitive inhibitor, CDDP might be 
bound to Zn2+-binding site at PAS and block the binding 
of positively charge BTCh to active center. 
CONCLUSION
The aim  of the  present  study  was  to  investigate  the 
interactions between rat intestinal BChE and four anti-
tumoral drugs (CDDP, CY, MTX or VINB) within their 
FIGURE 1. Time-dependent changes in the activities of the rat intesti-
nal BChE, when it is treated with 50 µM VINB (m), 50 µM MTX (l), 
25 µM CDDP (∆) or 25  (∆) or 25  (∆ µM CY (s) at 37oC. Initial velocities were 
measured at 4.0 mM BTCh.
FIGURE 2. The effects of increasing concentrations of VINB (l), 
MTX (m), CDDP (∆) or CY ( (∆) or CY ( (∆ s) on rat intestinal BChE activity at 
37oC. Initial velocities were measured at 4.0 mM BTCh.chemotherapeutic  concentration  ranges.  It  was  found 
that MTX and VINB do not have any important inhibi-
tory effects on BChE activity at 1-25 nM concentrations 
range, in vitro. However, approximately 20-30% inhibi-
tion in the BChE activity will be observed when CY and 
CDDP are used at therapeutic concentrations (100-200 
µM). It is clear that intestinal BChE constitutes the first 
line  of  defense  for  orally  introduced  drugs,  whereas 
serum  BChE  is  affected  by  intravenously  introduced 
drugs. Therefore, investigating the effect of CDDP, CY, 
MTX or VINB on human serum BChE will be more 
informative than intestinal BChE, because these drugs 
are given intravenously to cancer patients.
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FIGURE 3. The reciprocal plots in the absence of CDDP (m) and in 
the presence of 0.1 mM CDDP (∆); 0.2  (∆); 0.2  (∆ mM CDDP (l); 0.4 mM CDDP 
(s). Initial velocities were determined in 100 mM MOPS buffer, pH 
7.4,  using 0.025 mM DTNB, 0.25- 4.0 mM BTCh, and 182.5 ng puri-
fied enzyme in a final volume of 1 mL activity mixture, at 37oC.